NCT05316688View on ClinicalTrials.gov

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

January 20, 2026

Study Completion Date

January 20, 2027

Conditions
Oral Cavity Squamous Cell CarcinomaStage I Lip and Oral Cavity Cancer AJCC v8Stage II Lip and Oral Cavity Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage IVA Lip and Oral Cavity Cancer AJCC v8
Interventions
PROCEDURE

Near Infrared Imaging

Undergo NIR imaging

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

DRUG

Tozuleristide

Given IV

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Blaze Bioscience Inc.
All Listed Sponsors
collaborator

Blaze Bioscience Inc.

INDUSTRY

lead

University of Washington

OTHER